Prevalence and determinants of misclassification of the risk of recurrence of differentiated thyroid cancer after the first 131I post-therapeutic scintigraphy

Main Article Content

Nantaporn Wongsurawat
Charoonsak Somboonporn
Yutapong Raruenrom
Bandit Thinkhamrop

Abstract

131I total body scintigraphy has long been used for imaging the extent of disease in differentiated thyroid cancer (DTC). Currently, the risk of recurrence of DTC is stratified into low-, intermediate-, and high-risk based on pathological findings. In practice, 131I post-therapeutic scintigraphy after the first 131I treatment tends to detect additional cervical lymph node metastasis and/or distant functioning metastasis, which can guide the treatment, hence having a high impact on clinical outcome. The aim of our study is, therefore, to explore the prevalence of misclassification of the risk stratification system after the first dose of 131I therapy and to determine the factors associate with it. Misclassification was defined as the difference of the risk stratification between the one based on pathological findings and the other based on 131I post-therapeutic scintigraphy. Total of 360 patients was included. Of these, 57 patients were misclassified (15.8%). That is, 39 (10.8%) in the low-risk group should be in the intermediate group, 2 (0.6%) patients in the low-risk group should be in the high risk, and 16 (4.4%) patients in the intermediate group should be in the high-risk group. The baseline stimulated thyroglobulin (Tg) level of ≥ 10 ng/mL showed a strong association with the misclassification (OR=3.2, 95%CI: 1.4 to 7.5; p=0.007). In conclusion, detection of considerable number of misclassification in risk stratification of DTC has raised awareness of the under-prescription of 131I doses. Attention should be paid to patients with a high baseline stimulated Tg level of greater than 10 ng/mL.

Article Details

How to Cite
Wongsurawat, N., Somboonporn, C., Raruenrom, Y., & Thinkhamrop, B. (2021). Prevalence and determinants of misclassification of the risk of recurrence of differentiated thyroid cancer after the first 131I post-therapeutic scintigraphy . Asia-Pacific Journal of Science and Technology, 26(02), APST–26. https://doi.org/10.14456/apst.2021.15
Section
Research Articles

References

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1-133.

NCI [Internet]. Maryland: The Institute; c19370-2021[updated 2020 Mar 11; cited 2019 Mar 11]. Seer cancer stat facts: Thyroid cancer 2008-2014. Available from: https://seer.cancer/gov/statfacts/html/thyro/

html.

Tuttle RM, Haugen B, Perrier ND. Updated American joint committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why? Thyroid. 2017;27(6):751-756.

Thies ED, Tanase K, Maeder U, Luster M, Buck AK, Hänscheid H, et al. The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2014;41(12):2281-2290.

Qu Y, Huang R, Li L. Low-and high-dose radioiodine therapy for low-/intermediate-risk differentiated thyroid cancer: a preliminary clinical trial. Ann Nucl Med. 2017;31(1):71-83.

Seo M, Kim YS, Lee JC, Han MW, Kim ES, Kim KB, et al. Low-dose radioactive iodine ablation is sufficient in patients with small papillary thyroid cancer having minor extrathyroidal extension and central lymph node metastasis (T3 N1a). Clin Nucl Med. 2017;42(11):842-846.

Schmidt D, Szikszai A, Linke R, Bautz W, Kuwert T. Impact of 131I SPECT/SPIRAL CT on nodal staging of differentiated thyroid carcinoma at the first radioablation. J Nucl Med. 2009;50(1):18-23.

Grewal RK, Tuttle RM, Fox J, Borkar S, Chou JF, Gonen M, et al. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer. J Nucl Med. 2010;51(9):1361-1367.

Mizokami D, Kosuda S, Shiotani A, Kinoshita F, Saotome K, Morozumi K. Impact of 131I SPECT/CT on the management of differentiated thyroid carcinoma outpatients with radioablation. Nihon Jibiinkoka Gakkai Kaiho. 2014;117(5):673-680.

Hassan FU, Mohan HK. Clinical utility of SPECT/CT imaging post-radioiodine therapy: does it enhance patient management in thyroid cancer?. Eur Thyroid J. 2015;4(4):239-245.

Szujo S, Sira L, Bajnok L, Bodis B, Gyory F, Nemes O, et al. The impact of post-radioiodine therapy SPECT/CT on early risk stratification in differentiated thyroid cancer; a bi-institutional study. Oncotarget. 2017;8(45):79825-79834.

Zilioli V, Peli A, Panarotto MB, Magri G, Alkraisheh A, Wiefels C, et al. Differentiated thyroid carcinoma: incremental diagnostic value of 131I SPECT/CT over planar whole body scan after radioiodine therapy. Endocrine. 2017;56(3):551-559.

Verburg FA, Mader U, Reiners C, Hanscheid H. Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high-and low-risk patients. J Clin Endocrinol Metab. 2014;99(12):4487-4496.

Connor RJ. Sample size for testing differences in proportions for the paired-sample design. Biometrics. 1987;43(1):207-211.